2022
Use of Magnetic Resonance Imaging to Quantify Fat and Steatosis in the Pancreas in Patients after Bariatric Surgery: a Retrospective Study
BLAHO, Martin, Jitka MACHACKOVA, Petr DÍTĚ, Pavol HOLECZY, Petr SEDIVY et. al.Základní údaje
Originální název
Use of Magnetic Resonance Imaging to Quantify Fat and Steatosis in the Pancreas in Patients after Bariatric Surgery: a Retrospective Study
Autoři
BLAHO, Martin (203 Česká republika), Jitka MACHACKOVA (203 Česká republika), Petr DÍTĚ (203 Česká republika, domácí), Pavol HOLECZY, Petr SEDIVY (203 Česká republika), Robert PSAR (203 Česká republika), Zdenek SVAGERA (203 Česká republika), Dominik VILIMEK (203 Česká republika), Daniel TOMAN (203 Česká republika), Ondrej URBAN (203 Česká republika) a Marek BUZGA (203 Česká republika)
Vydání
OBESITY SURGERY, NEW YORK, SPRINGER, 2022, 0960-8923
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30219 Gastroenterology and hepatology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.900
Kód RIV
RIV/00216224:14110/22:00128219
Organizační jednotka
Lékařská fakulta
UT WoS
000859286600001
Klíčová slova anglicky
Obesity; Bariatric surgery; Metabolic syndrome; Pancreatic steatosis
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 23. 1. 2023 12:39, Mgr. Tereza Miškechová
Anotace
V originále
invasive method for diagnosing PS. We investigated the impact of metabolic syndrome (MS) on the presence of PS, differences in individuals with and without PS, and the metabolic effects of bariatric procedures. Methods Changes in anthropometric and basic biochemistry values and MS occurrence were evaluated in 34 patients with obesity who underwent a bariatric procedure. After the procedure, patients underwent MRI with manual 3D segmentation mask creation to determine the pancreatic fat content (PFC). We compared the differences in the PFC and the presence of PS in individuals with and without MS and compared patients with and without PS. Results We found no significant difference in the PFC between the groups with and without MS or in the occurrence of PS. There were significant differences in patients with and without PS, especially in body mass index (BMI), fat mass, visceral adipose tissue ( VAT), select adipocytokines, and lipid spectrum with no difference in glycemia levels. Significant metabolic effects of bariatric procedures were observed. Conclusions Bariatric procedures can be considered effective in the treatment of obesity, MS, and some of its components. Measuring PFC using MRI did not show any difference in relation to MS, but patients who lost weight to BMI < 30 did not suffer from PS and had lower overall fat mass and VAT. Glycemia levels did not have an impact on the presence of PS.